Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anrikefon Injection for postoperative pain control after laparoscopic gastrointestinal tumor resection
ChiCTR2600133658Phase 4Not yet recruiting
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- Sep 2026
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of hsk21542 in acute pain (2 arms), sponsored by The Affiliated Hospital of Xuzhou Medical University. Primary endpoint: Proportion of patients requiring rescue analgesia within 48 hours after surgery. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
hsk21542
03
Conditions
acute pain
Beyond the preview
Go deeper on ChiCTR2600133658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133658.